Literature DB >> 1594246

High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx.

R Maestro1, R Dolcetti, D Gasparotto, C Doglioni, S Pelucchi, L Barzan, E Grandi, M Boiocchi.   

Abstract

A series of 58 primary human squamous cell carcinomas of the larynx (LSCCs) was examined for the expression of the p53 tumor-suppressor gene by a combined immunohistochemical and molecular approach. About 60% of the cases displayed nuclear p53 overexpression as revealed by immunostaining with PAb1801, PAb122 and PAb240 monoclonal antibodies. This phenomenon was associated with the presence of structural and/or transcriptional alterations of the p53 gene. Our results provide evidence that p53 abnormalities constitute the most frequent genetic alteration identified so far in LSCC and indicate that the abnormal accumulation of the protein correlates with the presence of p53-mutated versions. These findings, taken together with the peculiar biochemical properties of p53, support the hypothesis of a possible pathogenetic relationship between smoke carcinogen exposure and p53 inactivation in the development of this tumor type.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594246

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

Review 1.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Authors:  Müjdat Yildirim; Jens Müller von der Grün; Ria Winkelmann; Emmanouil Fokas; Franz Rödel; Hanns Ackermann; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2017-01-31       Impact factor: 3.621

3.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

4.  In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

5.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; D Gasparotto; M Boiocchi; L Laurino; C D Fletcher
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

6.  Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.

Authors:  V Gorgoulis; V Zoumpourlis; G Rassidakis; A Karameris; C Barbatis; D A Spandidos; C Kittas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Tumor suppressor genes and related molecules in leiomyosarcoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; S Piccinin; D D Libera; M Boiocchi; C D Fletcher
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  p53 alterations in human squamous cell carcinomas and carcinoma cell lines.

Authors:  J Caamano; S Y Zhang; E A Rosvold; B Bauer; A J Klein-Szanto
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

9.  BCCIP as a prognostic marker for radiotherapy of laryngeal cancer.

Authors:  Amar Rewari; Huimei Lu; Rahul Parikh; Qifeng Yang; Zhiyuan Shen; Bruce G Haffty
Journal:  Radiother Oncol       Date:  2008-11-27       Impact factor: 6.280

10.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Authors:  E Latres; M Drobnjak; D Pollack; M R Oliva; M Ramos; M Karpeh; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.